Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

[1]  M. Muenter,et al.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.

[2]  Y. Agid,et al.  Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.

[3]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[4]  J. D. Parkes,et al.  "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.

[5]  Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects. , 1982, Advances in neurology.

[6]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[7]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[8]  T. H. Burnstine,et al.  Movement Disorders 2 , 1988, Neurology.

[9]  A. Grace,et al.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.

[10]  D J Brooks,et al.  Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[11]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[12]  H. Braak,et al.  Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[13]  S. Daniel,et al.  The anterior olfactory nucleus in Parkinson's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[14]  M. Stern,et al.  Prospects for gene therapy in Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[15]  Y. Agid,et al.  Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. , 1996, Advances in neurology.

[16]  A. Benabid,et al.  Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies , 1996, The European journal of neuroscience.

[17]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[18]  D. Dickson,et al.  The clinicopathologic spectrum of Lewy body disease. , 1996, Advances in neurology.

[19]  J. Cummings,et al.  The occurrence of depression in Parkinson's disease. A community-based study. , 1996, Archives of neurology.

[20]  T. Freeman.  From Transplants to Gene Therapy for Parkinson's Disease , 1997, Experimental Neurology.

[21]  O. Lindvall.  Neural transplantation: a hope for patients with Parkinson's disease , 1997, Neuroreport.

[22]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[23]  C. Goetz,et al.  Dopaminergic Transplants in Patients with Parkinson's Disease: Neuroanatomical Correlates of Clinical Recovery , 1997, Experimental Neurology.

[24]  U. Kang,et al.  Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[25]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[26]  O. Lindvall.  Update on fetal transplantation: the Swedish experience. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[27]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[28]  R. Hauser,et al.  Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[29]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[30]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[31]  W. Tatton,et al.  Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.

[32]  T. Itakura,et al.  Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3‐nitropropionic acid , 1999, Annals of neurology.

[33]  S. Daniel,et al.  Commentary Qjm Is Parkinson's Disease a Primary Olfactory Disorder? , 2022 .

[34]  Ornella Rimoldi,et al.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.

[35]  H. Braak,et al.  Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry , 1999, Neuroscience Letters.

[36]  P Riederer,et al.  Pathogenesis and preclinical course of Parkinson's disease. , 1999, Journal of neural transmission. Supplementum.

[37]  A. Parent,et al.  Dopaminergic innervation of human basal ganglia , 2000, Journal of Chemical Neuroanatomy.

[38]  O. Isacson,et al.  Transplantation of embryonic porcine mesencephalic tissue in patients with PD , 2000, Neurology.

[39]  G. Siegel,et al.  Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.

[40]  H. Braak,et al.  Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system , 2000, Acta Neuropathologica.

[41]  G. Glosser,et al.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease , 2000, Neurology.

[42]  G. Halliday,et al.  Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. , 2000, Brain : a journal of neurology.

[43]  J. Obeso,et al.  Pathophysiology of the basal ganglia in Parkinson's disease , 2000, Trends in Neurosciences.

[44]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  K. Jellinger.  Morphological substrates of mental dysfunction in Lewy body disease: an update. , 2000, Journal of neural transmission. Supplementum.

[46]  Y Agid,et al.  Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements , 2000, The European journal of neuroscience.

[47]  M. Inase,et al.  Protection against dopaminergic nigrostriatal cell death by excitatory input ablation , 2000, The European journal of neuroscience.

[48]  D. Aarsland,et al.  Risk of dementia in Parkinson’s disease , 2001, Neurology.

[49]  J. Jankovic,et al.  Daytime sleepiness and other sleep disorders in Parkinson’s disease , 2001, Neurology.

[50]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[51]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[52]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[53]  E. Bézard,et al.  Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys , 2001, Neurobiology of Disease.

[54]  B Bioulac,et al.  Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[55]  A. Björklund,et al.  Cell therapy in Parkinson's disease – stop or go? , 2001, Nature Reviews Neuroscience.

[56]  V. Dhawan,et al.  Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease , 2001, Annals of neurology.

[57]  A. Lang,et al.  Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. , 2002, JAMA.

[58]  A. Björklund,et al.  Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.

[59]  H. Braak,et al.  Parkinson’s disease: the thalamic components of the limbic loop are severely impaired by α-synuclein immunopositive inclusion body pathology , 2002, Neurobiology of Aging.

[60]  E. Arenas,et al.  Stem cells in the treatment of Parkinson’s disease , 2002, Brain Research Bulletin.

[61]  G. Halliday,et al.  Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. , 2002, Brain : a journal of neurology.

[62]  Versatile Cells Against Intractable Diseases , 2002, Science.

[63]  J. López-Barneo,et al.  Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson’s disease , 2002, Brain Research Bulletin.

[64]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[65]  R. Bakay,et al.  Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration , 2002, The Journal of Neuroscience.

[66]  Jia Luo,et al.  Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model , 2002, Science.

[67]  G. Halliday,et al.  Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. , 2002, Brain : a journal of neurology.

[68]  R. McKay,et al.  Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease , 2002, Nature.

[69]  A. Dagher,et al.  Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. , 2002, Journal of neurosurgery.

[70]  Bruce G. Jenkins,et al.  Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  E. Hirsch,et al.  Nondopaminergic neurons in Parkinson's disease. , 2003, Advances in neurology.

[72]  A. Björklund,et al.  Neural transplantation for the treatment of Parkinson's disease , 2003, The Lancet Neurology.

[73]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[74]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[75]  David J Brooks,et al.  Plasticity of the nigropallidal pathway in Parkinson's disease , 2003, Annals of neurology.

[76]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[77]  Kurt Jellinger,et al.  Amygdala pathology in Parkinson's disease , 2004, Acta Neuropathologica.